These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11355274)

  • 41. Cilostazol: a new drug in the treatment intermittent claudication.
    Kumar M; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
    Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K
    Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug treatment of intermittent claudication.
    Jacoby D; Mohler ER
    Drugs; 2004; 64(15):1657-70. PubMed ID: 15257627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cilostazol treatment of claudication in diabetic patients.
    Rendell M; Cariski AT; Hittel N; Zhang P
    Curr Med Res Opin; 2002; 18(8):479-87. PubMed ID: 12564659
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Randomized study of tolerability, safety and efficacy of Pletax in intermittent claudication].
    Kazantsev AN; Goriunov SV; Ershova OB; Erofeeva SB; Gurgenian EV
    Angiol Sosud Khir; 2021; 27(1):7-16. PubMed ID: 33825723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cilostazol.
    Cheng JW
    Heart Dis; 1999; 1(3):182-6. PubMed ID: 11720622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.
    Donnelly R
    Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S20-5. PubMed ID: 12180354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cilostazol for intermittent claudication.
    Med Lett Drugs Ther; 1999 May; 41(1052):44-6. PubMed ID: 10368703
    [No Abstract]   [Full Text] [Related]  

  • 52. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
    Stone WM; Demaerschalk BM; Fowl RJ; Money SR
    J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
    Ishiwata N; Noguchi K; Kawanishi M; Asakura Y; Hori M; Mitani A; Ito Y; Takahashi K; Nishiyama H; Shudo N; Takahashi S; Takahashi K; Tsuruzoe N; Nakaike S
    Life Sci; 2007 Sep; 81(12):970-8. PubMed ID: 17850826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication?
    Weismantel D
    J Fam Pract; 2001 Feb; 50(2):181. PubMed ID: 11219570
    [No Abstract]   [Full Text] [Related]  

  • 56. The US experience with cilostazol in treating intermittent claudication.
    Hiatt WR
    Atheroscler Suppl; 2005 Dec; 6(4):21-31. PubMed ID: 16275166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.
    Liang X; Wang Y; Zhao C; Cao Y
    PLoS One; 2022; 17(11):e0275392. PubMed ID: 36318524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
    Hong H; Mackey WC
    Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of cilostazol (Pletal) in the management of intermittent claudication.
    Bradbury AW
    Int J Clin Pract; 2003 Jun; 57(5):405-9. PubMed ID: 12846346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
    Lee C; Nelson PR
    Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.